Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Medical Sciences Division is delighted to welcome Dr Anjan Thakurta to Oxford, having now taken up his position of Visiting Professor of Cancer, Biology and Translational Science within the Radcliffe Department of Medicine.

None

Dr Thakurta will provide strategic support and advice to the Medical Sciences Division and foster new collaborations between the University of Oxford and Celgene. He will also facilitate greater access to and opportunities with senior Celgene scientists for University of Oxford researchers, enabling them to gain a deeper understanding of the scope and potential of Celgene’s portfolio of work and an industry perspective on research questions. Whilst in Oxford, Dr Thakurta will be based in the MRC Weatherall Institute of Molecular Medicine (MRC WIMM).

Dr Thakurta brings extensive knowledge of Celgene’s early therapeutic pipeline and translational biology programmes, especially in haematology / oncology, and over 20 years’ experience in translational and clinical drug development. Most recently, leading the myeloma disease team, one of Celgene’s major disease areas. Prior to this, he led translational and diagnostic work across all haematological areas in Celgene.

Dr Thakurta brings with him a wealth of experience in mentoring scientists in the early stages of their careers, and has previously supervised Oxford-Celgene fellows.  His advice on Oxford-Celgene Fellowship Programme applications will not only support the development of cutting-edge science, but also the training of the next generation of scientists and clinical academics.

 

As Visiting Professor, I will visit Oxford regularly, interact with current and potential future fellows and look forward to establishing some new and exciting collaborations and translational initiatives at the university over the next three years. - Dr Anjan Thakurta, Celgene

 

I am really pleased Dr Thakurta has been awarded the position of Visiting Professorship and has taken this up position. Dr Thakurta has a wealth of experience in drug development especially in haematological disease and has already mentored two young aspiring clinical academics, who have successfully started their independent careers in Oxford. He has also made important links with a number of Oxford groups and I am sure these new relationships will be enormously productive, helping to transform patient care as well as providing wonderful academic opportunities for Oxford University, Oxford University Hospitals NHS Foundation Trust and Celgene - Professor Paresh Vyas, Professor of Haematology, MRC Molecular Haematology Unit, MRC WIMM, University of Oxford

 

Similar stories

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.

New research reveals relationship between particular brain circuits and different aspects of mental wellbeing

Researchers at the University of Oxford have uncovered previously unknown details about how changes in the brain contribute to changes in wellbeing.

Night-time blood pressure assessment is found to be important in diagnosing hypertension

Around 15% of people aged 40-75 may have a form of undiagnosed high blood pressure (hypertension) that occurs only at night-time. Because they do not know about this, and therefore are not being treated for it, they are at a higher risk of cardiovascular disease such as stroke, heart failure, and even death, suggests new research from the University of Oxford published in the British Journal of General Practice.

Major new NIHR Global Health Research Unit to focus on data science and genomic surveillance of antimicrobial resistance

The Centre for Genomic Pathogen Surveillance, part of the Big Data Institute at the University of Oxford, has been awarded funding worth £7m for their work as an NIHR Global Health Research Unit (GHRU) for the next five years. The Centre’s research and capacity building work focuses on delivering genomics and enabling data for the surveillance of antimicrobial resistance (AMR).